Trial Profile
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects With Palmar Hyperhidrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Sofpironium bromide (Primary)
- Indications Hyperhidrosis
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals; Brickell Biotech; Fresh Tracks Therapeutics
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 03 Jun 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 18 Feb 2016 New trial record